



**Canada's Drug Agency**  
**L'Agence des médicaments du Canada**  
Drugs. Health Technologies and Systems. Médicaments, technologies de la santé et systèmes.

**Proposed Project Scope**

# **Dabrafenib-trametinib for BRAF V600E mutant anaplastic thyroid cancer**

Date: October 2024

## Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of dabrafenib-trametinib for BRAF V600E mutant anaplastic thyroid cancer.

**Table I: Policy Questions**

Item	Policy Question
1	Should dabrafenib-trametinib be publicly reimbursed for BRAF V600E mutant anaplastic thyroid cancer?

**Table II: Products Available in Canada**

Product	Manufacturer
Dabrafenib	Novartis
Trametinib	Novartis

## Project Description

**Table III: Project Scope**

Criteria	Description
Population	Patients with BRAF V600E mutant anaplastic thyroid cancer
Intervention(s)	Dabrafenib-trametinib
Comparators	Paclitaxel-carboplatin Docetaxel-doxorubicin Paclitaxel Doxorubicin
Outcomes	Overall response rate Duration of response Progression-free survival Overall survival Adverse events

**Table IV: Research Questions**

Item	Policy Question
1	What is the effectiveness of dabrafenib-trametinib for BRAF V600E mutant anaplastic thyroid cancer?
2	What are the harms associated with dabrafenib-trametinib for BRAF V600E mutant anaplastic thyroid cancer?
3	What is the expected cost of dabrafenib-trametinib for BRAF V600E mutant anaplastic thyroid cancer vs. other reimbursed regimens?

## **Key Project and Protocol Components**

This project will follow the [Procedures for Non-Sponsored Reimbursement Reviews](#).

## **Status of the Document**

This proposed project scope is being posted for information.